title: Novel synthesis of 2-[18F]-fluoroisonicotinic acid hydrazide and initial biological evaluation.
abstract: 2-[18F]-Fluoroisonicotinic acid hydrazide was synthesized by nucleophilic displacement reaction on ethyl-2- (trimethylammonium)-isonicotinate precursor in acetonitrile. Kryptofix 222 was used as the phase transfer catalyst. The intermediate fluorinated ethyl ester reacted with hydrazine hydrate to produce the hydrazide in excellent radiochemical yield. The overall radiochemical yield was greater than 70% with total synthesis time of approximately 60 minutes. Biological evaluation was performed in bacterial cells and biodistribution in normal CBA/J mice. It was found that the S. pneumoniae cells retained the radiotracer in an in vitro assay.
authors.affiliation: Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, 11211, Riyadh, Kingdom of Saudi Arabia. amarty@kfshrc.edu.sa
authors.forename: J K
authors.initials: JK
authors.lastname: Amartey
authors.forename: I
authors.initials: I
authors.lastname: Al-Jammaz
authors.forename: B
authors.initials: B
authors.lastname: Al-Otaibi
authors.forename: C
authors.initials: C
authors.lastname: Esguerra
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D005240:Feasibility Studies; D005260:Female; D006834:Hydrazines / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D007539:Isonicotinic Acids / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate; D051379:Mice; D008808:Mice, Inbred CBA; D009928:Organ Specificity; D011874:Radiometry / Q000379:methods; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics; D012016:Reference Values; D013296:Streptococcus pneumoniae / Q000378:metabolism*; D014018:Tissue Distribution; D014376:Tuberculosis / Q000000981:diagnostic imaging / Q000378:metabolism
chemical_list: C476778:2-fluoroisonicotinic acid hydrazide; D006834:Hydrazines; D007539:Isonicotinic Acids; D019275:Radiopharmaceuticals